TONIA SOPER: Open Payments
NPI 1720863814 · LISBON, CT. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,095 in 55 payments from 11 companies in 2025. Trend: 2023 $139 · 2024 $991 · 2025 $1,095
Food & beverage: $1,095
| Company | Payments | Amount |
|---|---|---|
| Novo Nordisk Inc | 14 | $283 |
| GlaxoSmithKline, LLC. | 9 | $205 |
| ABBVIE INC. | 12 | $182 |
| Lundbeck LLC | 3 | $80 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 4 | $70 |
| Astellas Pharma US Inc | 2 | $69 |
| Amgen Inc. | 4 | $66 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 3 | $54 |
| PFIZER INC. | 2 | $39 |
| AstraZeneca Pharmaceuticals LP | 1 | $28 |
Products named: Rybelsus, Ozempic, TRELEGY ELLIPTA, REXULTI, VRAYLAR, UBRELVY, AREXVY, JARDIANCE.
Industry payments across CT — which companies pay providers there.
